Altimmune: chief medical officer Christophe Arbet-Engels exercised 37,500 shares

What happened

• The filing reports that Christophe Arbet-Engels, chief medical officer, had exercise/conversion of derivative transactions (code M) for 37,500 shares on Oct 1, 2026 (one entry recorded as acquired at $0.00 and one entry recorded as disposed at $0.00) and a payment of exercise price or tax liability (code F) of 12,679 shares disposed at $2.76 for $34,994.
• Footnote language in the filing indicates the units were restricted stock units (RSUs) that vested and that shares were surrendered to cover taxes.

Key details

• Transaction date: Oct 1, 2026. Prices reported: $0.00 (exercise/conversion entries) and $2.76 (tax withholding). Total reported value for the tax withholding disposal: $34,994.
• Shares retained after withholding (37,500 vested minus 12,679 surrendered): 24,821 shares (based on the filing entries).
• Relevant footnotes from the filing:
  • Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock when vested.
  • Shares were surrendered to the issuer solely to cover taxes associated with vesting of RSUs.
  • The RSUs vest over four years with 25% vesting on Oct 1, 2026 and the remainder in equal annual installments for the following three years, subject to continued service; RSUs have no expiration date.
• Filing date: Oct 5, 2026. Filing timeliness is not specified in the filing.

Why it may matter

• The filing shows a conversion/vesting of RSUs with a partial surrender of shares to cover taxes (a sell-to-cover/tax withholding), not an open-market sale of all vested shares.
• This filing does not show why the insider traded or why the company acted.